132 related articles for article (PubMed ID: 32464274)
1. Molecular mechanisms of Guadecitabine induced FGFR4 down regulation in alveolar rhabdomyosarcomas.
Darvishi E; Slemmons K; Wan Z; Mitra S; Hou X; Hugues Parmentier J; Eddie Loh YH; Helman LJ
Neoplasia; 2020 Jul; 22(7):274-282. PubMed ID: 32464274
[TBL] [Abstract][Full Text] [Related]
2. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.
Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM
Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271
[TBL] [Abstract][Full Text] [Related]
3. KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance.
Xu W; Zhou B; Zhao X; Zhu L; Xu J; Jiang Z; Chen D; Wei Q; Han M; Feng L; Wang S; Wang X; Zhou J; Jin H
Int J Biol Sci; 2018; 14(9):1122-1132. PubMed ID: 29989047
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
[TBL] [Abstract][Full Text] [Related]
5. Histone demethylase lysine demethylase 5B in development and cancer.
Han M; Xu W; Cheng P; Jin H; Wang X
Oncotarget; 2017 Jan; 8(5):8980-8991. PubMed ID: 27974677
[TBL] [Abstract][Full Text] [Related]
6. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
Kristensen LH; Nielsen AL; Helgstrand C; Lees M; Cloos P; Kastrup JS; Helin K; Olsen L; Gajhede M
FEBS J; 2012 Jun; 279(11):1905-14. PubMed ID: 22420752
[TBL] [Abstract][Full Text] [Related]
7. PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma.
Marshall AD; van der Ent MA; Grosveld GC
Mol Carcinog; 2012 Oct; 51(10):807-15. PubMed ID: 21882254
[TBL] [Abstract][Full Text] [Related]
8. FGFR4 signaling couples to Bim and not Bmf to discriminate subsets of alveolar rhabdomyosarcoma cells.
Wachtel M; Rakic J; Okoniewski M; Bode P; Niggli F; Schäfer BW
Int J Cancer; 2014 Oct; 135(7):1543-52. PubMed ID: 24550147
[TBL] [Abstract][Full Text] [Related]
9. KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer.
Xhabija B; Kidder BL
Semin Cancer Biol; 2019 Aug; 57():79-85. PubMed ID: 30448242
[TBL] [Abstract][Full Text] [Related]
10. Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions.
Xue S; Lam YM; He Z; Zheng Y; Li L; Zhang Y; Li C; Mbadhi MN; Zheng L; Cheng Z; Liu Y; Wang X; Chan LC; Ng RK; Zhang J
Exp Hematol; 2020 Feb; 82():53-65. PubMed ID: 32007477
[TBL] [Abstract][Full Text] [Related]
11. KDM5B focuses H3K4 methylation near promoters and enhancers during embryonic stem cell self-renewal and differentiation.
Kidder BL; Hu G; Zhao K
Genome Biol; 2014 Feb; 15(2):R32. PubMed ID: 24495580
[TBL] [Abstract][Full Text] [Related]
12. The PHD1 finger of KDM5B recognizes unmodified H3K4 during the demethylation of histone H3K4me2/3 by KDM5B.
Zhang Y; Yang H; Guo X; Rong N; Song Y; Xu Y; Lan W; Zhang X; Liu M; Xu Y; Cao C
Protein Cell; 2014 Nov; 5(11):837-50. PubMed ID: 24952722
[TBL] [Abstract][Full Text] [Related]
13. The KDM5 family of histone demethylases as targets in oncology drug discovery.
Rasmussen PB; Staller P
Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
[TBL] [Abstract][Full Text] [Related]
14. Structure of the Arabidopsis JMJ14-H3K4me3 Complex Provides Insight into the Substrate Specificity of KDM5 Subfamily Histone Demethylases.
Yang Z; Qiu Q; Chen W; Jia B; Chen X; Hu H; He K; Deng X; Li S; Tao WA; Cao X; Du J
Plant Cell; 2018 Jan; 30(1):167-177. PubMed ID: 29233856
[TBL] [Abstract][Full Text] [Related]
15. Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B.
Pippa S; Mannironi C; Licursi V; Bombardi L; Colotti G; Cundari E; Mollica A; Coluccia A; Naccarato V; La Regina G; Silvestri R; Negri R
Molecules; 2019 May; 24(9):. PubMed ID: 31060229
[No Abstract] [Full Text] [Related]
16. Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.
Zheng YC; Chang J; Wang LC; Ren HM; Pang JR; Liu HM
Eur J Med Chem; 2019 Jan; 161():131-140. PubMed ID: 30343192
[TBL] [Abstract][Full Text] [Related]
17. SUMOylation negatively modulates target gene occupancy of the KDM5B, a histone lysine demethylase.
Bueno MT; Richard S
Epigenetics; 2013 Nov; 8(11):1162-75. PubMed ID: 23970103
[TBL] [Abstract][Full Text] [Related]
18. Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27.
Wang D; Han S; Peng R; Jiao C; Wang X; Yang X; Yang R; Li X
J Exp Clin Cancer Res; 2016 Feb; 35():37. PubMed ID: 26911146
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
20. Coordinated regulation of retinoic acid signaling pathway by KDM5B and polycomb repressive complex 2.
Zhang Y; Liang J; Li Q
J Cell Biochem; 2014 Sep; 115(9):1528-38. PubMed ID: 24619877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]